Volpe MA, Cabelin M, Te AE, et al. A prospective trial using saw palmetto versus finasteride in the treatment of chronic nonbacterial prostatitis (CP). Presented at: American Urological Association 2001 Annual Meeting; June 2 - 7, 2001; Anaheim, Calif.
Emili E, Lo Cigno M, Petrone U. Clinical trial of a new drug for treating hypertrophy of the prostate (Permixon®) [in Italian].
Urologia.
1983;50:1042 - 1048.
Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant
Serenoa repens
in benign prostatic hyperplasia.
Br J Clin Pharmacol. 1984;18:461 - 462.
Tasca A, Barulli M, Cavazzana A, et al. Treatment of obstructive symptomology caused by prostatic adenoma using an extract of
Serenoa repens. Double-blind clinical study vs. placebo [in Italian; English abstract].
Minerva Urol Nefrol.
1985;37:87 - 91.
Boccafoschi C, Annoscia S. Comparison of
Serenoa repens
extract with placebo by controlled clinical trial in patients with prostatic adenomatosis [in Italian].
Urologia.
1983;50:1257 - 1268.
Smith HR, Memon A, Smart CJ, et al. The value of Permixon® in benign prostatic hypertrophy.
Br J Urol.
1986;58:36 - 40.
Descotes JL, Rambeaud JJ, Deschaseaux P, et al. Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after exclusion of placebo responders.
Clin Drug Invest.
1995;9:291 - 297.
Mattei FM, Capone M, Acconcia A.
Serenoa repens
extract in the medical treatment of benign prostatic hypertrophy [in Italian].
Urologia. 1988;55:547 - 552.
Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients.
Prostate.
1996;29:231 - 240.
Debruyne F, Koch G, Boyle P, et al. Comparison of a phytotherapeutic agent(Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benignprostatic hyperplasia: a one-year randomized international study.
Eur Urol.
2002;41:497-507.
Menchini-Fabris GF, Giorgi P, Andreini F, et al. New perspectives on the use of
Pygeum Africanum
in prostato-bladder pathology [in Italian; English abstract].
Arch Ital Urol Nefrol Androl.
1988;60:313 - 322.
Carani C, Salvioli V, Scuteri A, et al. Urological and sexual evaluation of treatment of benign prostatic disease using at high doses [in Italian; English abstract].
Arch Ital Urol Nefrol Androl. 1991;63:341 - 345..
Bombardelli E, Morazzoni P.
Prunus africana
(Hook. f.) Kalkm.
Fitoterapia.
1997;68:205 - 218.
Bongi G. Tadenan in the treatment of prostatic adenoma. Anatomo-clinical study [in Italian].
Minerva Urol.
1972;24:129 - 139.
Rizzo M. Terapia medica dell'adenoma della prostata: Valutazione clinica comparativa tra estratto di Pygeum africanum ad alte dosi e placebo.
Farmacia Terapia.
1985;2:105 - 110.
Ranno S, Minaldi G, Viscusi G, et al. Efficacy and tolerability of prostate adenoma treatment with Tadenan 50 [in Italian; English abstract].
Prog Med. 1986;42:165 - 169.
Bassi P, Artibani W, De Luca V, et al. Standardized extract of
Pygeum Africanum
in the treatment of benign prostatic hypertrophy. Controlled clinical study versus placebo [in Italian].
Minerva Urol Nefrol.
1987;39:45 - 50.
Barlet A, Albrecht J, Aubert A, et al. Efficacy of
Pygeum africanum
extract in the medical therapy of urination disorders due to benign prostatic hyperplasia: evaluation of objective and subjective parameters. A placebo-controlled double-blind multicenter study [translated from German].
Wien Klin Wochenschr.
1990;102:667 - 673.
Rhodes L, Primka RL, Berman C, et al. Comparison of finasteride (Proscar), a 5-alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5-alpha reductase inhibition.
Prostate.
1993;22:43 - 51.
Andro MC, Riffaud JP.
Pygeum Africanum
extract for the treatment of patients with benign prostatic hyperplasia: a review of 25 years of published experience.
Curr Ther Res.
1995;56:796 - 817.
Kozai K, Miyake Y, Kohda H, et al. Inhibition of glucosyltransferase from
Streptococcus mutans
by oleanolic acid and ursolic acid.
Caries Res.
1987;21:104 - 108.
Yablonsky F, Nicolas V, Riffaud JP, et al. Antiproliferative effect of
Pygeum Africanum
extract on rat prostatic fibroblasts.
J Urol.
1997;157:2381 - 2387.
Vontobel HP, Herzog R, Rutishauser G, et al. Results of a double-blind study on the effectiveness of ERU (extractum radicis Urticae) capsules in conservative treatment of benign prostatic hyperplasia [translated from German].
Urologe A. 1985;24:49 - 51.
Dathe G, Schmid H. Phytotherapy of benign prostate hyperplasia (BPH); double-blind study with stinging nettle root extract (Extractum Radicis Urticae - ERU) [translated from German].
Urólogo B. 1987;27:223 - 226.
European Scientific Cooperative on Phytotherapy.
Urticae radix. Exeter, UK: ESCOP; 1996 - 1997; Monographs on the Medicinal Uses of Plant Drugs, Fascicule 2:4.
Wilt TJ, MacDonald R, Ishani A. Beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review.
BJU Int.
1999;83:976-983.
Klippel KF, Hiltl DM, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group.
Br J Urol. 1997;80:427 - 432.
Kadow C, Abrams PH. A double-blind trial of the effect of beta-sitosteryl glucoside (WA184) in the treatment of benign prostatic hyperplasia.
Eur Urol. 1986;12:187 - 189.
Berges RR, Windeler J, Trampisch HJ, et al. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group.
Lanceta.
1995;345:1529 - 1532.
Berges RR, Windeler J, Trampisch HJ, et al. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group.
Lanceta. 1995;345:1529 - 1532.
Berges RR, Kassen A, Senge T. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up.
BJU Int.
2000;85:842 - 846.
Klippel KF, Hiltl DM, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group.
Br J Urol. 1997;80:427 - 432.
Becker H, Ebeling L. Conservative therapy of benign prostate hyperplasia (BPH) with Cernilton®N. Results of a placebo-controlled double-blind study [translated from German].
Urologe [B]. 1988;28:301 - 306.
Buck AC, Cox R, Rees RWM, et al. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton:a double-blind, placebo-controlled study.
Br J Urol. 1990;66:398 - 404.
Maekawa M, Kishimoto T, Yasumoto R, et al. Clinical evaluation of Cernilton on benign prostatic hypertrophy-a multiple center double-blind study with Paraprost [in Japanese; English abstract].
Hinyokika Kiyo. 1990;36:495 - 516.
Dutkiewicz S. Usefulness of Cernilton in the treatment of benign prostatic hyperplasia.
Int Urol Nephrol. 1996;28:49 - 53.
Becker H, Ebeling L. Conservative therapy of benign prostate hyperplasia (BPH) with Cernilton®N. Results of a placebo-controlled double-blind study [translated from German].
Urologe [B]. 1988;28:301 - 306.
Buck AC, Cox R, Rees RWM, et al. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton:a double-blind, placebo-controlled study.
Br J Urol. 1990;66:398 - 404.
Loschen G, Ebeling L. Inhibition of the arachidonate metabolism by an extract of rye pollen [in German; English abstract].
Arzneimittelforschung. 1991;41:162 - 167.
Sokeland J. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome.
BJU Int. 2000;86:439 - 442.
Marks LS, Partin AW, Epstein JI, et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia.
J Urol.
2000;163:1451 - 1456.
Wilt T, Ishani A, MacDonald R, et al.
Pygeum Africanum
for benign prostatic hyperplasia.
Cochrane Database Syst Rev.
2002;1:CD001044.
Gerber GS, Kuznetsov D, Johnson BC, et al. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms.
Urología.
2001;58:960-964.
Preuss HG, Marcusen C, Regan J, et al. Randomized trial of a combination of natural products (cernitin, Saw Palmetto, B-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH).
Int Urol Nephrol.
2001;33:217-225.
La información aquí suministrada complementa la atención recibida por su médico. De ninguna forma intenta sustituir el consejo de un professional medico. LLAME A SU MEDICO DE INMEDIATO SI PIENSA QUE PODRIA TENER UNA EMERGENCIA. Siempre busque consejo médico antes de comenzar un nuevo tratamiento o si tiene preguntas sobre una condición médica.